346 related articles for article (PubMed ID: 28842494)
1. Cellular prion protein targets amyloid-β fibril ends via its C-terminal domain to prevent elongation.
Bove-Fenderson E; Urano R; Straub JE; Harris DA
J Biol Chem; 2017 Oct; 292(41):16858-16871. PubMed ID: 28842494
[TBL] [Abstract][Full Text] [Related]
2. The cellular prion protein traps Alzheimer's Aβ in an oligomeric form and disassembles amyloid fibers.
Younan ND; Sarell CJ; Davies P; Brown DR; Viles JH
FASEB J; 2013 May; 27(5):1847-58. PubMed ID: 23335053
[TBL] [Abstract][Full Text] [Related]
3. Exosomal cellular prion protein drives fibrillization of amyloid beta and counteracts amyloid beta-mediated neurotoxicity.
Falker C; Hartmann A; Guett I; Dohler F; Altmeppen H; Betzel C; Schubert R; Thurm D; Wegwitz F; Joshi P; Verderio C; Krasemann S; Glatzel M
J Neurochem; 2016 Apr; 137(1):88-100. PubMed ID: 26710111
[TBL] [Abstract][Full Text] [Related]
4. High molecular mass assemblies of amyloid-β oligomers bind prion protein in patients with Alzheimer's disease.
Dohler F; Sepulveda-Falla D; Krasemann S; Altmeppen H; Schlüter H; Hildebrand D; Zerr I; Matschke J; Glatzel M
Brain; 2014 Mar; 137(Pt 3):873-86. PubMed ID: 24519981
[TBL] [Abstract][Full Text] [Related]
5. Accumulation of cellular prion protein within β-amyloid oligomer plaques in aged human brains.
Takahashi RH; Yokotsuka M; Tobiume M; Sato Y; Hasegawa H; Nagao T; Gouras GK
Brain Pathol; 2021 Sep; 31(5):e12941. PubMed ID: 33624334
[TBL] [Abstract][Full Text] [Related]
6. A d-enantiomeric peptide interferes with heteroassociation of amyloid-β oligomers and prion protein.
Rösener NS; Gremer L; Reinartz E; König A; Brener O; Heise H; Hoyer W; Neudecker P; Willbold D
J Biol Chem; 2018 Oct; 293(41):15748-15764. PubMed ID: 30131337
[TBL] [Abstract][Full Text] [Related]
7. Systematic and standardized comparison of reported amyloid-β receptors for sufficiency, affinity, and Alzheimer's disease relevance.
Smith LM; Kostylev MA; Lee S; Strittmatter SM
J Biol Chem; 2019 Apr; 294(15):6042-6053. PubMed ID: 30787106
[TBL] [Abstract][Full Text] [Related]
8. The anti-prion RNA aptamer R12 disrupts the Alzheimer's disease-related complex between prion and amyloid β.
Iida M; Mashima T; Yamaoki Y; So M; Nagata T; Katahira M
FEBS J; 2019 Jun; 286(12):2355-2365. PubMed ID: 30916478
[TBL] [Abstract][Full Text] [Related]
9. Interaction between human prion protein and amyloid-beta (Abeta) oligomers: role OF N-terminal residues.
Chen S; Yadav SP; Surewicz WK
J Biol Chem; 2010 Aug; 285(34):26377-83. PubMed ID: 20576610
[TBL] [Abstract][Full Text] [Related]
10. Structural details of amyloid β oligomers in complex with human prion protein as revealed by solid-state MAS NMR spectroscopy.
König AS; Rösener NS; Gremer L; Tusche M; Flender D; Reinartz E; Hoyer W; Neudecker P; Willbold D; Heise H
J Biol Chem; 2021; 296():100499. PubMed ID: 33667547
[TBL] [Abstract][Full Text] [Related]
11. Dextran sulfate sodium inhibits amyloid-β oligomer binding to cellular prion protein.
Aimi T; Suzuki K; Hoshino T; Mizushima T
J Neurochem; 2015 Aug; 134(4):611-7. PubMed ID: 25963375
[TBL] [Abstract][Full Text] [Related]
12. Soluble Prion Peptide 107-120 Protects Neuroblastoma SH-SY5Y Cells against Oligomers Associated with Alzheimer's Disease.
Rezvani Boroujeni E; Hosseini SM; Fani G; Cecchi C; Chiti F
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33019683
[TBL] [Abstract][Full Text] [Related]
13. Cellular prion protein participates in amyloid-β transcytosis across the blood-brain barrier.
Pflanzner T; Petsch B; André-Dohmen B; Müller-Schiffmann A; Tschickardt S; Weggen S; Stitz L; Korth C; Pietrzik CU
J Cereb Blood Flow Metab; 2012 Apr; 32(4):628-32. PubMed ID: 22293988
[TBL] [Abstract][Full Text] [Related]
14. Aβ induces its own prion protein N-terminal fragment (PrPN1)-mediated neutralization in amorphous aggregates.
Béland M; Bédard M; Tremblay G; Lavigne P; Roucou X
Neurobiol Aging; 2014 Jul; 35(7):1537-48. PubMed ID: 24602510
[TBL] [Abstract][Full Text] [Related]
15. Prion protein stabilizes amyloid-β (Aβ) oligomers and enhances Aβ neurotoxicity in a
Younan ND; Chen KF; Rose RS; Crowther DC; Viles JH
J Biol Chem; 2018 Aug; 293(34):13090-13099. PubMed ID: 29887525
[TBL] [Abstract][Full Text] [Related]
16. Cellular prion protein mediates the toxicity of beta-amyloid oligomers: implications for Alzheimer disease.
Nygaard HB; Strittmatter SM
Arch Neurol; 2009 Nov; 66(11):1325-8. PubMed ID: 19901162
[TBL] [Abstract][Full Text] [Related]
17. Identification of prion protein-derived peptides of potential use in Alzheimer's disease therapy.
Nieznanska H; Bandyszewska M; Surewicz K; Zajkowski T; Surewicz WK; Nieznanski K
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt A):2143-2153. PubMed ID: 29604335
[TBL] [Abstract][Full Text] [Related]
18. Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein.
Balducci C; Beeg M; Stravalaci M; Bastone A; Sclip A; Biasini E; Tapella L; Colombo L; Manzoni C; Borsello T; Chiesa R; Gobbi M; Salmona M; Forloni G
Proc Natl Acad Sci U S A; 2010 Feb; 107(5):2295-300. PubMed ID: 20133875
[TBL] [Abstract][Full Text] [Related]
19. Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons.
Um JW; Nygaard HB; Heiss JK; Kostylev MA; Stagi M; Vortmeyer A; Wisniewski T; Gunther EC; Strittmatter SM
Nat Neurosci; 2012 Sep; 15(9):1227-35. PubMed ID: 22820466
[TBL] [Abstract][Full Text] [Related]
20. Cellular prion protein as a therapeutic target in Alzheimer's disease.
Laurén J
J Alzheimers Dis; 2014; 38(2):227-44. PubMed ID: 23948943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
